Distinct pituitary hormone levels of 184 Chinese children and adolescents with multiple pituitary hormone deficiency: a single-centre study.
Adolescents
Children
Multiple pituitary hormone deficiency
Pituitary hormone levels
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
14 11 2019
14 11 2019
Historique:
received:
10
04
2019
accepted:
04
11
2019
entrez:
15
11
2019
pubmed:
15
11
2019
medline:
10
10
2020
Statut:
epublish
Résumé
Pituitary tumors and/or their treatment are associated with multiple pituitary hormone deficiency (MPHD) in adults, but the distinct pituitary hormone profile of MPHD in Chinese children and adolescents remains unclear. Patients with MPHD were divided into four groups according to their MRI results: 1) pituitary stalk interruption syndrome (PSIS); 2) hypoplasia; 3) normal; and 4) tumor survivor. Among the 184 patients, 93 patients (50.5%) were with PSIS, 24 (13.0%) had hypoplastic pituitary gland, 10 (5.4%) patients were normal, and 57 (31.0%) were tumor survivors. There was an association between abnormal fetal position and PSIS (P ≤ 0.001). The CA/BA in PSIS, hypoplasia, normal, tumor survivor groups were 2.27 ± 1.05, 1.48 ± 0.39, 1.38 ± 0.57, 1.49 ± 0.33, and HtSDS were - 3.94 ± 1.39, - 2.89 ± 1.09, - 2.50 ± 1.05, - 1.38 ± 1.63. Patients in PSIS group had the largest CA/BA (P ≤ 0.001 vs. hypoplasia group, P = 0.009 vs. normal group, P ≤ 0.001 vs. tumor survivors) and lowest HtSDS (P ≤ 0.001 vs. hypoplasia group, P = 0.003 vs. normal group, P ≤ 0.001 vs. tumor survivors). The levels of TSH in the PSIS, hypoplasia, normal, and tumor survivor groups were 1.03 ± 1.08 (P = 0.149 vs. tumor survivors), 1.38 ± 1.47 (P = 0.045 vs. tumor survivors), 2.49 ± 1.53 (P < 0.001 vs. tumor survivors), and 0.76 ± 1.15 μIU/ml. The levels of GH peak in PSIS, hypoplasia, normal, tumor survivor groups were 1.37 ± 1.78, 1.27 ± 1.52, 3.36 ± 1.79, 0.53 ± 0.52 ng/ml and ACTH were 27.50 ± 20.72, 25.05 ± 14.64, 34.61 ± 59.35, 7.19 ± 8.63 ng/ml. Tumor survivors had the lowest levels of GH peak (P ≤ 0.001 vs. PSIS group, P = 0.002 vs. hypoplasia group, P ≤ 0.001 vs. normal group) and ACTH (all the P ≤ 0.001 vs. the other three groups). The frequency of PSIS is high among children and adolescents with MPHD. The severity of hormone deficiencies in patients with MPHD was more important in the tumor survivor group compared with the other groups.
Sections du résumé
BACKGROUND
Pituitary tumors and/or their treatment are associated with multiple pituitary hormone deficiency (MPHD) in adults, but the distinct pituitary hormone profile of MPHD in Chinese children and adolescents remains unclear.
METHODS
Patients with MPHD were divided into four groups according to their MRI results: 1) pituitary stalk interruption syndrome (PSIS); 2) hypoplasia; 3) normal; and 4) tumor survivor.
RESULTS
Among the 184 patients, 93 patients (50.5%) were with PSIS, 24 (13.0%) had hypoplastic pituitary gland, 10 (5.4%) patients were normal, and 57 (31.0%) were tumor survivors. There was an association between abnormal fetal position and PSIS (P ≤ 0.001). The CA/BA in PSIS, hypoplasia, normal, tumor survivor groups were 2.27 ± 1.05, 1.48 ± 0.39, 1.38 ± 0.57, 1.49 ± 0.33, and HtSDS were - 3.94 ± 1.39, - 2.89 ± 1.09, - 2.50 ± 1.05, - 1.38 ± 1.63. Patients in PSIS group had the largest CA/BA (P ≤ 0.001 vs. hypoplasia group, P = 0.009 vs. normal group, P ≤ 0.001 vs. tumor survivors) and lowest HtSDS (P ≤ 0.001 vs. hypoplasia group, P = 0.003 vs. normal group, P ≤ 0.001 vs. tumor survivors). The levels of TSH in the PSIS, hypoplasia, normal, and tumor survivor groups were 1.03 ± 1.08 (P = 0.149 vs. tumor survivors), 1.38 ± 1.47 (P = 0.045 vs. tumor survivors), 2.49 ± 1.53 (P < 0.001 vs. tumor survivors), and 0.76 ± 1.15 μIU/ml. The levels of GH peak in PSIS, hypoplasia, normal, tumor survivor groups were 1.37 ± 1.78, 1.27 ± 1.52, 3.36 ± 1.79, 0.53 ± 0.52 ng/ml and ACTH were 27.50 ± 20.72, 25.05 ± 14.64, 34.61 ± 59.35, 7.19 ± 8.63 ng/ml. Tumor survivors had the lowest levels of GH peak (P ≤ 0.001 vs. PSIS group, P = 0.002 vs. hypoplasia group, P ≤ 0.001 vs. normal group) and ACTH (all the P ≤ 0.001 vs. the other three groups).
CONCLUSION
The frequency of PSIS is high among children and adolescents with MPHD. The severity of hormone deficiencies in patients with MPHD was more important in the tumor survivor group compared with the other groups.
Identifiants
pubmed: 31722706
doi: 10.1186/s12887-019-1819-6
pii: 10.1186/s12887-019-1819-6
pmc: PMC6854793
doi:
Substances chimiques
Pituitary Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
441Références
Zhonghua Er Ke Za Zhi. 2009 Jul;47(7):487-92
pubmed: 19951507
Lancet. 2016 Nov 12;388(10058):2403-2415
pubmed: 27041067
Exp Ther Med. 2017 Jun;13(6):3474-3478
pubmed: 28587427
J Pediatr Endocrinol Metab. 2000 Feb;13(2):171-8
pubmed: 10711662
Maturitas. 2012 Aug;72(4):277-85
pubmed: 22727068
Sudan J Paediatr. 2017;17(1):30-35
pubmed: 29213168
J Pediatr Endocrinol Metab. 2015 Jan;28(1-2):19-26
pubmed: 25514328
Ann Endocrinol (Paris). 2012 Apr;73(2):53-5
pubmed: 22521856
Growth Horm IGF Res. 2016 Apr;27:46-52
pubmed: 26947989
Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):43-60
pubmed: 21396574
Int J Endocrinol. 2016;2016:6365830
pubmed: 27118970
Neuroendocrinology. 2011;93(3):181-8
pubmed: 21304225
AJNR Am J Neuroradiol. 1998 Sep;19(8):1495-9
pubmed: 9763384
Eur J Pediatr. 2014 May;173(5):589-95
pubmed: 24257915
Zhonghua Er Ke Za Zhi. 2009 Jul;47(7):493-8
pubmed: 19951508
Int J Endocrinol. 2017;2017:6969286
pubmed: 28702053
Best Pract Res Clin Endocrinol Metab. 2016 Dec;30(6):679-691
pubmed: 27974184
N Engl J Med. 2005 Sep 15;353(11):1171-6
pubmed: 16162890
Clin Neurol Neurosurg. 2012 Feb;114(2):149-55
pubmed: 22056762
Growth Horm IGF Res. 2017 Dec;37:19-25
pubmed: 29107171
J Clin Endocrinol Metab. 1999 Jul;84(7):2408-13
pubmed: 10404812
Eur J Endocrinol. 2000 Oct;143(4):493-6
pubmed: 11022195
AJNR Am J Neuroradiol. 1998 Oct;19(9):1609-15
pubmed: 9802480
Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):461-9
pubmed: 22863388
BMJ Open. 2015 Feb 25;5(2):e006107
pubmed: 25716173
Physiol Rev. 2012 Jan;92(1):1-38
pubmed: 22298650
Eur J Endocrinol. 2017 Jun;176(6):R269-R282
pubmed: 28258131
Insights Imaging. 2015 Apr;6(2):241-60
pubmed: 25794595
F1000Res. 2017 Feb 22;6:178
pubmed: 28299199